Therefore, this study uncovers a novel molecular mechanism by which HDAC3 inhibits STING transcription via β-estradiol-ERα, and provides a promising therapy with a combination of HDAC and STING for combating endometrial cancer. The gene discussed is HDAC3; the disease is endometrial cancer.